Coronavirus vaccine could be on market in mid-2021, says unlisted German company
Follow UsStory highlights
CureVac might be able to apply for approval early next year, Klaus Cichutek, President of German vaccine regulator PEI, added during a joint video conference.
A vaccine against the coronavirus pandemic by CureVac could be on the market in mid-2021, the unlisted German company said on Wednesday.
CureVac might be able to apply for approval early next year, Klaus Cichutek, President of German vaccine regulator PEI, added during a joint video conference.
With this, CureVac will become the second company after rival BioNTech to launch human trials of an experimental coronavirus vaccine in the country.
The trial launch will see 144 participants in Germany and Belgium receive different dosages of the vaccine and a further 24 getting a placebo.
First meaningful results could be available in September or October, and approval could be on the cards under favourable conditions in the middle of next year.
A larger Phase II trial could start in September or October, provided first Phase I read-outs are promising, the company said.
The World Health Organisation lists 11 experimental coronavirus vaccines as currently being tested on humans.
The German government on Monday unveiled a deal to take an agreed 23% stake in CureVac for a cash injection of 300 million euros ($338 million).
Germany and partner countries in the European Union last week pledged funds for the production of an experimental vaccine being developed by the University of Oxford and AstraZeneca, saying they needed to spread their bets across several more candidates.
The company, based in Tuebingen and backed by the Bill & Melinda Gates Foundation, is using the so-called messenger RNA approach, like BioNTech and its partner Pfizer as well as Moderna.
(with inputs from Reuters)